Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in one of three expansion cohorts in the Phase 1 trial evaluating VIR-5500,
Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000
09:13am, Sunday, 12'th Apr 2026
72,559 shares were sold for a total transaction value of ~$664,000 on April 6, 2026. This sale represented 6.76% of De Backer's total holdings at the time of the transaction.
Backer Marianne De Sells 72,559 Shares of Vir Biotechnology (NASDAQ:VIR) Stock
04:03am, Thursday, 09'th Apr 2026
Vir Biotechnology, Inc. (NASDAQ: VIR - Get Free Report) CEO Backer Marianne De sold 72,559 shares of the firm's stock in a transaction on Monday, April 6th. The stock was sold at an average price of $
Vir Biotechnology, Inc. $VIR Shares Sold by Citigroup Inc.
03:40am, Monday, 09'th Mar 2026
Citigroup Inc. reduced its position in Vir Biotechnology, Inc. (NASDAQ: VIR) by 22.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exch
Vir Biotechnology to Participate in Upcoming Investor Conferences
04:05pm, Thursday, 26'th Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of Mar
Vir Biotechnology Announces Pricing of Public Offering of Common Stock
10:31pm, Wednesday, 25'th Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing
Vir Biotechnology Announces Proposed Public Offering of Common Stock
04:05pm, Tuesday, 24'th Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish
01:30pm, Tuesday, 24'th Feb 2026
Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at hi
These Analysts Boost Their Forecasts On Vir Biotechnology
01:05pm, Tuesday, 24'th Feb 2026
Vir Biotechnology reported a fourth-quarter loss of 31 cents, beating the consensus loss of 41 cents. Sales reached $64.07 million, surpassing the consensus of $23.18 million.
U.S. stock futures rose on Tuesday after closing lower on Monday. Futures of all the major benchmark indices were positive following a sell-off.
What's Happening With VIR Stock?
04:10am, Tuesday, 24'th Feb 2026
Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer treatment, VIR-5500, along with encouraging P
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
02:04am, Tuesday, 24'th Feb 2026
Vir Biotechnology, Inc. (VIR) Q4 2025 Earnings Call Transcript
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates
09:56pm, Monday, 23'rd Feb 2026
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.76 per share a year ago.
Vir Biotech Catapults 65% On A $1.71 Billion Deal With Astellas
07:13pm, Monday, 23'rd Feb 2026
Vir stock catapulted late Monday after the small biotech company smashed fourth-quarter sales views and signed a deal with Astellas Pharma.
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
05:14pm, Monday, 23'rd Feb 2026
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025. �
